A new COVID-19 medication has been approved in Abu Dhabi for the treatment of mild to moderate cases and those who have had direct contact with a patient.
The emirate's Department of Health (DoH) has partnered with Swiss healthcare company Roche to provide casirivimab and imdevimab to certain categories of patients.
The antibody combination has already been approved in the European Union and Japan, and conditionally approved in the UK and Australia.
It is also authorised for emergency use in the United States, India, Switzerland and Canada, and is recommended by the World Health Organisation (WHO).
.@DoHSocial has partnered with Swiss healthcare company @Roche to provide a new Covid-19 medication, approved for emergency use, to treat mild to moderate Covid-19 cases and those who have had direct contact with a positive case.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 1, 2021
Read more: https://t.co/vGQXyUvhGB pic.twitter.com/Yj9JxVgemP
UAE postpones vehicle licensing limit for residents
UAE Government Annual Meetings key to reviewing national priorities
New pedestrian bridge links Dubai Mall Metro Station and Coca-Cola Arena
High-achieving Union teams honoured at UAE Government Annual Meetings
Al Gergawi: UAE accelerates development with over AED 4 trillion in projects
